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The bone marrow and/or peripheral blood from 126 patients with acute myeloid leukemia
(AML), 57 with chronic myeloid leukemia (CML), 91 with acute lymphocytic leukemia (ALL),
and 178 normal controls were analyzed using a polymerase chain reaction-restriction
fragment length polymorphism (RFLP) assay to evaluate the association of the endostatin
polymorphisms D104N (nucleotide 4349G→A) with leukemia. In the 178 normal Taiwanese,
the allele frequency of 4349G was 98% (348/356) and that of 4349A was 2% (8/356). The
frequencies of homozygous 4349G (104D/D) and heterozygous 4349G/A (104D/N) were 95.
5% (170/178) and 4.5% (8/178), respectively. However, no individuals were homozygous
4349A (104N/N). Among the leukemia patients, 124/126 with AML (98.4%), 55/57 with CML
(94.9%), and 89/91 with ALL (97.9%) were homozygous 4349G. In addition, 2/126 with AML
(1.6%), 2/57 with CML (5.1%), and 2/91 with ALL (2.1%) were heterozygous 4349G/A. No
patients were homozygous 4349A. Similar frequencies of endostatin polymorphisms were
observed in leukemic patients and normal controls. This suggests that the endostatin poly-
morphism is not associated with the risk of leukemia.
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The molecular pathogenesis of different kinds of
cancer, including leukemia, involves a stepwise accu-
mulation of mutations affecting both cellular
oncogenes and tumor suppressor genes [1–3]. Other
factors including genetic instability and genetic vari-
ations in drug metabolism have been explored [4, 5].
Other gene alterations may be associated with the risk
or progression of leukemia.
Recently, angiogenesis has been suggested as a
fundamental step in tumor progression and metasta-
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sis [6, 7]. Excessive angiogenesis is characteristic of a
variety of pathologic conditions including cancer for-
mation and metastasis [6, 8]. A series of angiogenic
and antiangiogenic molecules that mediate the se-
quential steps involved in tumor angiogenesis have
been described [6, 9]. Several angiogenic inhibitors
have been identified: α-interferon, platelet factor 4,
thrombospondin-1, angiostatin, the 16-kd fragment of
prolactin, the 29-kd fragment of fibronectin, and
endostatin [6, 9, 10]. Many of these inhibitors, includ-
ing endostatin, are stored as cryptic parts of naturally
occurring large precursor proteins that are not them-
selves angiogenic inhibitors [9, 10]. Endostatin, a po-
tent inhibitor of angiogenesis, is a 20-kd fragment
derived from the carboxyl-terminal of collagen XVIII
(exons 41 to 43) that inhibits endothelial cell
proliferation, migration, and angiogenesis [7, 11, 12].
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Endostatin binds to the heparan-sulfated proteoglycan
situated on the endothelial cell surface, which induces
apoptosis through tyrosine kinase signaling (via the
Shb adaptor protein) and significant reduction of the
anti-apoptotic proteins Bcl-2 and Bcl-XL [10, 13].
Endostatin is present in the vascular basement mem-
brane and frequently in elastic fibers and microfibrils
[7, 10, 14]. The serum level of endostatin is sufficient to
effectively inhibit endothelial cell proliferation in vitro.
It has recently been reported that lower expression of
the endostatin precursor (collagen XVIII) is associated
with progression of human hepatocellular carcinoma
[15]. Higher serum levels of endostatin induce regres-
sion of solid tumors in animals [16]. In addition, the
endostatin polymorphism (D104N) predisposes to a
higher risk of prostate adenocarcinoma [17]. Therefore,
lower levels of endostatin could be associated with a
higher risk of developing solid tumors. However, the
association of endostatin polymorphisms with the risk
of leukemia has not yet been studied. To elucidate
endostatin polymorphisms in leukemia, cases of acute
myeloid leukemia (AML), chronic myeloid leukemia
(CML), and acute lymphocytic leukemia (ALL) were
compared with normal controls. Polymorphism analy-
sis was performed using a polymerase chain reaction
(PCR)-restriction fragment length polymorphism
(RFLP) assay; some representative cases were analyzed
using direct sequencing.
MATERIALS AND METHODS
Tumor samples and normal controls
Specimens of bone marrow and/or peripheral blood
were obtained from 126 de novo cases of AML, 57
cases of CML, and 91 cases of ALL diagnosed at the
Kaohsiung Medical University Hospital in 1996
through 2001. In addition, peripheral blood samples
from 178 normal controls were also collected.
DNA amplification and restriction enzyme
analysis
Total genomic DNA was prepared from bone marrow
or peripheral blood leukocytes of subjects as described
previously [18]. Oligonucleotide primer design and
restriction enzyme analysis was conducted according
to the methods of Iughetti et al [17]. We designed PCR
primers to identify the endostatin D104N polymor-
phism (nucleotide 4349G→A of the collagen XVIII
cDNA in NM_030582). The sequences of the forward
and reverse  primers  used for  PCR were 5 ' -
C A C G G T T T C T C T T C C A G G A C - 3 '  a n d  5 ' -
CTCTCAGAGCTGCTCACACG-3', respectively. DNA
amplification was performed as described previously
[19, 20], except that the annealing temperature was
modified based on the melting temperature of the
primers. The 169-bp amplified fragments were di-
gested with the restriction enzyme Mse I and sepa-
rated by electrophoresis in 2.5–3.5% agarose gel.
Sequence analysis
Several wild and mutant endostatin alleles were fur-
ther analyzed by direct sequencing to confirm the
results. The amplicons were purified using a gel ex-
traction kit (Geneclean III Kit, Bio101, Inc., CarlsbadCA,
USA), then sequenced using the SequiTherm ExcelTM II
DNA Sequencing Kit (Epicentre®Technologies,
Madison, WI, USA). The sequencing primers were
those used for PCR.
Statistical methods
Descriptive analysis was performed to present the
frequencies and distributions of demographic
variables. Genotype frequencies in leukemia patients
and normal controls were compared using contin-
gency table analysis and the chi-square test. The odds
ratio and its confidence interval were estimated using
standard methods. The analysis was performed using
SAS 6.11 statistical software.
RESULTS
Changes in the D104N endostatin pattern after restric-
tion enzyme digestion are shown in the Figure. The
169-bp PCR product was undigested in the 4349G
Figure. Enzyme digestion analysis of the polymerase chain
reaction product for endostatin D104N polymorphism. Lanes 1,
2, 3, 5, 6, and 7 are homozygous D/D and lane 4 is a D/N
heterozygote. M is a 100-bp ladder marker.
Endostatin polymorphism in leukemia
3Kaohsiung J Med Sci January 2003 • Vol 19 • No 1
allele, but it was cleaved to 101- and 68-bp fragments
in the 4349A allele.
The distribution of D104N polymorphisms is shown
in the Table. Among the 178 normal Taiwanese, the
4349G (104D) allele was more common than the 4349A
(104N) allele (98% vs. 2%), and homozygosity for
4349G was more common than heterozygosity (95.5%
vs. 4.5%); there was no homozygosity for 4349A.
Of the leukemia patients, most were homozygous
for 4349G (AML: 98.4%; CML: 94.9%; ALL: 97.9%). The
remaining patients were heterozygous; there was no
homozygosity for 4349A.
DISCUSSION
In this study, we found that the frequency of endostatin
D104N in the Taiwanese population (q = 0.05) is sig-
nificantly different from that of Caucasians (q = 0.16)
(p < 0.001), but is quite similar to that in blacks (q =
0.08) reported by Iughetti et al [17]. No controls or
leukemia patients were homozygous for N104N
endostatin, similar again to the data reported by
Iughetti et al [17]. This result is consistent with our
previous study on the CYP3A5 polymorphism, which
suggested that inter-individual and interracial differ-
ences exist [21].
A number of polymorphic genes that may modify
the effects of carcinogens, including the cytochrome
p 4 5 0 ,  g l u t a t h i o n e  S - t r a n s f e r a s e ,  a n d  N -
acetyltransferase enzymes, are associated with a high
risk of cancer susceptibility [22, 23]. Recently, a series
of angiogenic and anti-angiogenic molecules involved
in tumor angiogenesis have been described [6, 8, 9],
and there is evidence that excessive angiogenesis is
characteristic of cancer formation and metastasis.
Leukemia and other hematological malignancies are
also angiogenesis-dependent [24–26]. Padro et al noted
increased angiogenesis in the bone marrow of AML
patients and suggested the involvement of angiogen-
esis in the pathophysiology of AML [25]. Scappaticci
et al reported angiogenesis-dependent leukemia in a
mouse model [26], and the angiogenesis inhibitor
endostatin was found to inhibit bone marrow
angoiogenesis in leukemia in an animal study [11].
Polymorphisms in the angiogenesis-related endostatin
gene and its precursor collagen XVIII are associated
with a risk of cancer susceptibility in prostatic adeno-
carcinoma and hepatocellular carcinoma [15, 17]. These
studies suggest that endostatin polymorphisms may
be associated with a risk of leukemogenesis.
Endostatin is an important angiogenesis inhibitor,
which acts by binding to heparin/heparan sulfate.
Although D104 is not included in the binding epitope,
Iughetti et al hypothesized that inhibition occurs
through binding to other molecules [17]. We examined
the frequencies of the endostatin D104N polymor-
phism in AML, CML, and ALL. There were no signifi-
cant differences between any of these diseases and
healthy controls (p = 0.161, 0.748, and 0.346, respectively).
The results showed that the endostatin D104N poly-
morphism in the Taiwanese population is not relevant
to leukemogenesis. Consequently, we recommend that
interracial differences in endostatin, differences in the
pathogenesis of prostatic adenocarcinoma and
leukemia, and the potential role of the endostatin in
leukemia are studied further.
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